Introduction
Protein kinases-intracellular enzymes that modulate cellular functions-play a pivotal role in the
signal transduction processes that regulate many key biological processes. Abnormalities in these signal
transduction pathways are implicated in the etiology of numerous diseases, which has motivated
pharmaceutical companies to pursue protein kinases as drug targets-a trend that now accounts for
20-30% of all drug discovery programs.
Get the Answers You Need to Shape Your Strategy
- The protein kinase family is a mostly unexploited class of drug targets. Novartis's kinase inhibitor
Gleevec, approved in 2001 for CMS, boasts sales of $3 billion worldwide in 2007. What effect has
Gleevec's success had on the development of new kinase inhibitors?
- Most major pharmaceutical companies are avidly pursuing kinase inhibitor development both internally
and/or in collaboration with biotech companies. Which Big Pharma players have kinase
inhibitor development programs underway? What are some of the key collaborations and alliances
that have formed around kinase targets? What is the current state of the kinase inhibitor
development pipeline?
- Whereas development of kinase inhibitors in the past has been hindered by the perceived complexity
of the process, technological advances will drive the future development of kinase inhibitors.
What are some of the technologies that have aided the development of new kinase inhibitors?
How has technology altered the choice of drug targets and disease indications being pursued
by pharma companies?
-
At present, oncology patients have derived the most benefit from kinase inhibitors, although
the potential exists for patients with longer-term chronic conditions to benefit. What
chronic conditions are under investigation for treatment with kinase inhibitors? What
difficulties or opportunities lie on the path of such agents' approval?
Scopecurrent state of the kinase inhibitor market; potential market
influences.
About protein kinases: protein kinase family classifications; structure and function of the
kinase and its inhibitors; current screening procedures.
Kinase inhibitor selectivity: why selectivity is important and how it can be determined.
Development challenges: the influences of mutations and drug resistance; p38 MAP
kinases.
Pharmacogenomics: the influence of genetic variation on kinase inhibitor efficacy.
Profiles: select companies employing novel technologies and strategies in kinase research.
Market outlook: our general forecast for the direction and success of protein kinase
inhibitors. Please note, the PDF e-mail from publisher version of this report is for a global site license.
|
Additional Information
Companies Mentioned in This Spectrum Report
- ActivX Biosciences
- Ambit Biosciences
- Amgen
- Amphora Discovery
- Ariad Pharmaceuticals
- Array Biopharma
- Asahi Kasei Pharma
- Astellas Pharma
- Astex Therapeutics
- AstraZeneca
- Bayer
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Carna Biosciences
- Cephalon
- Cyclacel
- Eli Lilly
- Emiliem
- EntreMed
- Exelixis
- Galapagos
- Genentech
- GlaxoSmithKline
- Invitrogen
- Janssen Pharmaceutica (Johnson & Johnson)
- Johnson & Johnson
- Kinaxo Biosciences
- Kinex Pharmaceuticals
- KuDos Pharmaceuticals
- Locus Pharmaceuticals
- Merck & Co.
- Merck Serono
- Miikana Therapeutics
- Millennium Pharmaceuticals
- Millipore
- Mitsubishi Pharma
- Montigen
- Novartis
- Ono Pharmaceutical
- Pfi zer
- Pharmacopeia
- ProQinase
- Reaction Biology
- Rigel Pharmaceuticals
- Roche
- Sanofi -Aventis
- Scios
- Schering AG
- SGX Pharmaceuticals
- Sugen
- TargeGen
- Vertex Pharmaceuticals
- Wyeth
